Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: A study of 367 myeloma patients

Bone Marrow Transplantation

Volumn 37, Issue 9, 2006, Pages 857-864

  Miceli, M H ^a   Dong, L ^a   Grazziutti, M L ^a   Fassas, A ^a   Thertulien, R ^a   Van Rhee, F ^a   Barlogie, B ^a   Anaissie, E J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Infection; Iron; Neutropenia; Smoking; Stem cell transplantation

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; GATIFLOXACIN; IRON; LEVOFLOXACIN; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER REGRESSION; COLITIS; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GENDER; HUMAN; INCIDENCE; INFECTION; INFECTION RISK; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; MYELOMA; NEUTROPENIA; NEUTROPHIL COUNT; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; SEPTIC SHOCK; SMOKING;

ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; INFECTION; IRON OVERLOAD; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; STEM CELL TRANSPLANTATION; THALIDOMIDE;

EID: 33646049725     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705340     Document Type: Article

References (46)

1. Gahrton G. Progress in hematopoietic stem cell transplantation in multiple myeloma. Curr Opin Hematol 2005; 12: 463-470.
2. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Effect of adding thalidomide to the treatment of multiple myeloma with tandem autotransplants. N Engl J Med 2006 (in press).
3. Anaissie E, Jacobson J, Fassas A, Zangari M, Thertulien R, van Rhee F et al. Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients. In: 45th American Society of Hematology Annual Meeting 2003; 6 December 2003; San Diego, 2003.
4. Perez-Simon JA, Martin A, Caballero D, Corral M, Nieto MJ, Gonzalez M et al. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 1279-1283.
5. Fujii K, Aoyama M, Shinagawa K, Matsuo K, Takenaka K, Ikeda K et al. Risk of neutropenic fever and early infectious complications after autologous peripheral blood stem cell transplantation for malignant diseases. Int J Hematol 2002; 76: 186-191.
6. O'Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: Recent developments. Hematology (Am Soc Hematol Educ Program) 2003; 1: 438-472.
7. Anaissie E, Nucci M. Risks and epidemiology of infections after autologous stem cell transplantation. In: Bowden RA, Ljungman P, Paya CV (eds). Transplant Infections, 2nd edn. Lippincott Williams & Wilkins: Philadelphia, 2003, pp 39-50.
8. Nosanchuk JD, Sepkowitz KA, Pearse RN, White MH, Nimer SD, Armstrong D. Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant 1996; 18: 355-359.
9. Engels EA, Ellis CA, Supran SE, Schmid CH, Barza M, Schenkein DP et al. Early infection in bone marrow transplantation: Quantitative study of clinical factors that affect risk. Clin Infect Dis 1999; 28: 256-266.
10. Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: Etiology and potential risk factors. Am J Med 1999; 106: 191-197.
11. Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 2001; 32: 391-395.
12. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128-140.
13. Marx JJ. Iron and infection: Competition between host and microbes for a precious element. Best Pract Res Clin Haematol 2002; 15: 411-426.
14. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program) 2003; 1: 40-61.
15. National Nosocomial Infections Surveillance (NNIS). National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000; 28: 429-448.
16. Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Iron and infection: The heart of the matter. FEMS Immunol Med Microbiol 2005; 43: 325-330.
17. Schaible UE, Kaufmann SH. Iron and microbial infection. Nat Rev Microbiol 2004; 2: 946-953.
18. Sunder-Plassmann G, Patruta SI, Horl WH. Pathobiology of the role of iron in infection. Am J Kidney Dis 1999; 34 (4 Suppl 2): S25-S29.
19. Hoen B. Iron and infection: Clinical experience. Am J Kidney Dis 1999; 34 (4 Suppl 2): S30-S34.
20. Clark TD, Semba RD. Iron supplementation during human immunodeficiency virus infection: A double-edged sword? Med Hypotheses 2001; 57: 476-479.
21. Bergmann TK, Vinding K, Hey H. Multiple hepatic abscesses due to Yersinia enterocolitica infection secondary to primary haemochromatosis. Scand J Gastroenterol 2001; 36: 891-895.
22. Hopfner M, Nitsche R, Rohr A, Harms D, Schubert S, Folsch UR. Yersinia enterocolitica infection with multiple liver abscesses uncovering a primary hemochromatosis. Scand J Gastroenterol 2001; 36: 220-224.
23. Moalem S, Weinberg ED, Percy ME. Hemochromatosis and the enigma of misplaced iron: Implications for infectious disease and survival. Biometals 2004; 17: 135-139.
24. Wang SC, Lin KH, Chern JP, Lu MY, Jou ST, Lin DT et al. Severe bacterial infection in transfusion-dependent patients with thalassemia major. Clin Infect Dis 2003; 37: 984-988.
25. Maertens J, Demuynck H, Verbeken EK, Zachee P, Verhoef GE, Vandenberghe P et al. Mucormycosis in allogeneic bone marrow transplant recipients: Report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24: 307-312.
26. Kubota N, Miyazawa K, Shoji N, Sumi M, Nakajima A, Kimura Y et al. A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy. Haematologica 2003; 88: EIM13.
27. Hor LI, Chang YK, Chang CC, Lei HY, Ou JT. Mechanism of high susceptibility of iron-overloaded mouse to Vibrio vulnificus infection. Microbiol Immunol 2000; 44: 871-878.
28. Thuma PE, Olivieri NF, Mabeza GF, Biemba G, Parry D, Zulu S et al. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans. Am J Trop Med Hyg 1998; 58: 358-364.
29. Gomes MS, Boelaert JR, Appelberg R. Role of iron in experimental Mycobacterium avium infection. J Clin Virol 2001; 20: 117-122.
30. Mencacci A, Cenci E, Boelaert JR, Bucci P, Mosci P, Fe d'Ostiani C et al. Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis 1997; 175: 1467-1476.
31. Strasser SI, Kowdley KV, Sale GE, McDonald GB. Iron overload in bone marrow transplant recipients. Bone Marrow Transplant 1998; 22: 167-173.
32. Altes A, Remacha AF, Sarda P, Sancho FJ, Sureda A, Martino R et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 2004; 34: 505-509.
33. Altes A, Remacha AF, Sureda A, Martino R, Briones J, Canals C et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 987-989.
34. Lesic B, Foulon J, Carniel E. Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica. Antimicrob Agents Chemother 2002; 46: 1741-1745.
35. Duffy T. Microcytic and hypochromic anemias. In: Goldman Lee AD (ed). Cecil Textbook of Medicine, 22nd edn. Saunders: Philadelphia, 2004, pp 1003-1009.
36. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med 2004; 164: 2206-2216.
37. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
38. Rex JH, Anaissie EJ, Boutati E, Estey E, Kantarjian H. Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: A retrospective review of 833 episodes of neutropenia in 322 adults. Leukemia 2002; 16: 1197-1199.
39. Tricot G, Barlogie B, Van Rhee F. Treatment advances in multiple myeloma. Br J Haematol 2004; 125: 24-30.
40. Pecora AL. Impact of stem cell dose on hematopoietic recovery in autologous blood stem cell recipients. Bone Marrow Transplant 1999; 23 (Suppl 2): S7-S12.
41. Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000; 110: 292-299.
42. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004; 363: 357-362.
43. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342: 681-689.
44. Dignani C, Mahfouz M, EJ A. Prevention of infections in patients with hematologic malignancy. In: Wiernick G, Dutcher and Kyle (eds). Neoplastic Disease of the Blood, 4th edn. Cambridge University Press, North American Branch: Stanford, 2003.
45. Grima KM. Therapeutic apheresis in hematological and oncological diseases. J Clin Apher 2000; 15: 28-52.
46. Valbonesi M, Bruni R. Clinical application of therapeutic erythrocytapheresis (TEA). Transfus Sci 2000; 22: 183-194.